| 1 |
33499685 | Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. | 2021 May |
1 |
| 2 |
33790574 | Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. | 2021 |
1 |
| 3 |
34174987 | The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. | 2021 Aug |
1 |
| 4 |
32442869 | Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs. | 2020 Aug 5 |
1 |
| 5 |
33061448 | Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. | 2020 |
1 |
| 6 |
31064155 | Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. | 2019 May 6 |
2 |
| 7 |
29191916 | Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. | 2018 Feb 22 |
1 |
| 8 |
29522278 | Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells. | 2018 Apr |
1 |
| 9 |
30067771 | The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. | 2018 |
1 |
| 10 |
28017967 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). | 2017 Sep |
1 |
| 11 |
28364000 | Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ. | 2017 May 15 |
1 |
| 12 |
27174919 | Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. | 2016 Jun 28 |
3 |
| 13 |
25917267 | The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. | 2015 Sep |
1 |
| 14 |
25024054 | Phosphoinositide 3-kinase inhibitors in lymphoma. | 2014 Sep |
1 |
| 15 |
25258342 | IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. | 2014 Dec 4 |
1 |
| 16 |
24211136 | PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. | 2013 Nov 21 |
2 |
| 17 |
24267274 | Two birds with one stone: dual p110δ and p110γ inhibition. | 2013 Nov 21 |
1 |